1. Home
  2. M vs PTCT Comparison

M vs PTCT Comparison

Compare M & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Macy's Inc

M

Macy's Inc

HOLD

Current Price

$25.61

Market Cap

6.5B

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$73.13

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
M
PTCT
Founded
1830
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.7B
IPO Year
2003
2006

Fundamental Metrics

Financial Performance
Metric
M
PTCT
Price
$25.61
$73.13
Analyst Decision
Hold
Buy
Analyst Count
13
17
Target Price
$20.09
$80.65
AVG Volume (30 Days)
4.6M
1.3M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
3.97%
N/A
EPS Growth
12.08
264.48
EPS
0.23
0.90
Revenue
$22,621,000,000.00
$264,734,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$17.70
P/E Ratio
$109.26
$78.72
Revenue Growth
N/A
36.19
52 Week Low
$12.02
$43.18
52 Week High
$26.59
$90.87

Technical Indicators

Market Signals
Indicator
M
PTCT
Relative Strength Index (RSI) 56.27 37.38
Support Level $22.32 $68.16
Resistance Level $25.87 $72.09
Average True Range (ATR) 0.85 3.11
MACD 0.11 -0.99
Stochastic Oscillator 61.03 39.28

Price Performance

Historical Comparison
M
PTCT

About M Macy's Inc

Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: